An immune-mediated relationship between the brain and skin has been hypothesized in previous studies about psoriasis.
A version of this article was originally published on HCPLive. This version has been lightly edited.
New research examined brain structure and connectivity in patients to observe the effects of psoriasis in relation to depression.
An immune-mediated relationship between the brain and skin has been hypothesized in psoriasis before, according to Georgia Lada, MD, Dermatology Centre, Salford Royal NHS Foundation Trust, National Institute for Health Research Manchester Biomedical Research Centre, The University of Manchester.
This brain imaging study from Lada and her team was the first to look at the position of depression and systemic inflammation in brain measures with the largest sample of patients with psoriasis to date. Depression coexists with psoriasis in up to 25% of patients.
Data of 1048 brain magnetic resonance imaging (MRI) cases from the UK Biobank were assessed. Study populations included 131 patients with comorbid psoriasis and depression, who were matched by age and sex to 131 non-depressed patients with psoriasis. Then, 393 patients with depression served as a control group, along with 393 non-depressed controls.
"Interaction effects of psoriasis and depression on volume, thickness and surface of a-priori defined regions of interest (ROIs), white matter tracts and 55x55 partial correlation resting-state connectivity matrices were investigated using general linear models," investigators wrote. "Linear regression was employed to test associations of brain measures with C-reactive protein (CRP) and neutrophil counts."
With the presence of depression, increased thickness in the right precuneus was evident in patients with psoriasis compared with controls. This thickening demonstrated a marginal correlation with recurrent lifetime suicidality in patients with depression and psoriasis.
Findings revealed no differences in regional, global brain volumes, or white matter integrity compared with controls without psoriasis or psoriatic arthritis (PsA). Unrelated to depression comorbidity, patients with coexisting psoriasis and PsA showed fronto-occipital decoupling in resting-state connectivity compared to patients without joint involvement and controls.
Investigators reported that CRP and neurophil counts did not predict precuneus thickness and fronto-occipital connectivity.
"Our findings provide evidence for a combined effect of psoriasis and depression on the precuneus, which is not directly linked to systemic inflammation, and may relate to suicidality or altered somatosensory processing," the team concluded. "The use of the UK Biobank may limit generalizability of results in populations with severe disease."
The study was published in Brain, Behavior, & Immunity Health.
Reference
Ladaab G, Talbot PS, Chinoy H, Warren RB, McFarquhar M, Kleyn CE. Brain structure and connectivity in psoriasis and associations with depression and inflammation; findings from the UK biobank. Brain Behav Immun Health. Published online November 21, 2022. doi:10.1016/j.bbih.2022.100565
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof cream.
Read More
Psoriasis as an Inflammatory Disease, and What’s Changed Over Time
August 3rd 2021August is National Psoriasis Awareness Month, and on this episode of Managed Care Cast, we bring you an excerpt of an interview with a New Jersey dermatologist about the changing concept of psoriasis as more than just a skin disease.
Listen
Study Finds Link Between Depression, Functional Impairment in Psoriasis, Psoriatic Arthritis
November 24th 2023Depression symptoms are often underdiagnosed and undertreated in patients with psoriasis and psoriatic arthritis, contributing to a worsened quality of life (QOL). However, a recent study found that depression, functional impairment, and worsened QOL are related.
Read More
Evaluating Work Productivity, Efficacy and Safety of Tildrakizumab in Patients With Plaque Psoriasis
November 13th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.
Read More
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More